In NSCLC, several potential novel drug combinations are currently under investigation, including phase II trials of platinum-based chemotherapy plus nivolumab in combination with relatlimab as first-line therapy (NCT04623775); eftilagimod alpha, a soluble fusion protein of LAG-3 and the human IgG Fc moiety, in combination with pembrolizumab as treatment for patients who showed resistance to anti-PD-1/PD-L1 therapy (NCT03625323); and favezelimab, an anti-LAG-3 antibody, in combination with pembrolizumab (NCT03516981). The gene discussed is LAG3; the disease is non-small cell lung carcinoma.